Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Shin

Showing results (111-120 of 139) with videos related to

Pageof 14
Sort By:
Oncogene|February 21, 2017
Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasisL Jin, J Chun, C Pan, et al.
Journal of the National Cancer Institute|July 1, 1992
Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancerJ S Lee, H I Libshitz, F V Fossella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancerF R Khuri, J R Rigas, R A Figlin, et al.
Archives of Otolaryngology--Head & Neck Surgery|October 16, 1999
Biochemoprevention for dysplastic lesions of the upper aerodigestive tractV A Papadimitrakopoulou, G L Clayman, D M Shin, et al.
Cancer|September 1, 1991
Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancerJ S Lee, H I Libshitz, F V Fossella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancerF V Fossella, S M Lippman, D M Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1997
Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemopreventionD M Shin, X C Xu, S M Lippman, et al.
Journal of the National Cancer Institute|April 17, 1996
p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinomaD M Shin, J S Lee, S M Lippman, et al.
Seminars in Radiation Oncology|April 21, 1999
A pilot clinical laboratory trial of paclitaxel and endobronchial brachytherapy in patients with non-small cell lung cancerJ S Lee, R Komaki, R C Morice, et al.
Journal of the National Cancer Institute|January 6, 2000
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expressionD M Shin, L Mao, V M Papadimitrakopoulou, et al.
Pageof 14

Showing results (111-120 of 139) with videos related to

Sort By:
Pageof 14
Oncogene|February 21, 2017
Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasisL Jin, J Chun, C Pan, et al.
Journal of the National Cancer Institute|July 1, 1992
Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancerJ S Lee, H I Libshitz, F V Fossella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancerF R Khuri, J R Rigas, R A Figlin, et al.
Archives of Otolaryngology--Head & Neck Surgery|October 16, 1999
Biochemoprevention for dysplastic lesions of the upper aerodigestive tractV A Papadimitrakopoulou, G L Clayman, D M Shin, et al.
Cancer|September 1, 1991
Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non-small cell lung cancerJ S Lee, H I Libshitz, F V Fossella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancerF V Fossella, S M Lippman, D M Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1997
Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemopreventionD M Shin, X C Xu, S M Lippman, et al.
Journal of the National Cancer Institute|April 17, 1996
p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinomaD M Shin, J S Lee, S M Lippman, et al.
Seminars in Radiation Oncology|April 21, 1999
A pilot clinical laboratory trial of paclitaxel and endobronchial brachytherapy in patients with non-small cell lung cancerJ S Lee, R Komaki, R C Morice, et al.
Journal of the National Cancer Institute|January 6, 2000
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expressionD M Shin, L Mao, V M Papadimitrakopoulou, et al.
Pageof 14